-+ 0.00%
-+ 0.00%
-+ 0.00%

Maxim Group Maintains Buy on Anebulo Pharmaceuticals, Lowers Price Target to $3

Benzinga·05/15/2025 17:14:29
Listen to the news
Maxim Group analyst Michael Okunewitch maintains Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy and lowers the price target from $6 to $3.